Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
AVROBIO Inc
AVRO
$
14.99
0.33%
Sat December 26th, 2020
10:01
Analysis
Avrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 Catalysts
Seeking Alpha
Fri December 25th, 2020
15:00
Analysis
AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Seeking Alpha
Thu October 1st, 2020
06:54
Analysis
Protalix Could Claim Substantial Global Market Share In Fabry Disease
Seeking Alpha
Tue September 29th, 2020
14:48
Analysis
AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status
Zacks
Mon September 14th, 2020
17:51
Analysis
AVROBIO (AVRO) Presents At 18th Annual Global Healthcare Virtual Conference - Slideshow
Seeking Alpha
Fri September 11th, 2020
14:56
Analysis
AVROBIO (AVRO) Investor Presentation - Slideshow
Seeking Alpha
Thu August 13th, 2020
22:02
Analysis
AVROBIO (AVRO) Presents At 2020 Wedbush PacGrow Healthcare Conference - Slideshow
Seeking Alpha
Mon July 27th, 2020
12:23
Analysis
AVROBIO Sees Hammer Chart Pattern: Time to Buy?
Zacks
